A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma.

Priya U KumthekarSean Aaron GrimmRoxanne T AlemanMarc C ChamberlainDavid SchiffPatrick Y WenFabio Massaiti IwamotoDemirkan Besim GurselDavid A ReardonBenjamin PurowMasha KocherginskiIrene HelenowskiJeffrey J Raizer

Published in: Neuro-oncology advances (2022)

This study showed BEV is well tolerated and appears to be a promising systemic treatment option for patients with recurrent and refractory meningiomas.

Keyphrases

randomized controlled trial
clinical trial
combination therapy
replacement therapy